The first Sharing Progress in Neonatology (SPIN) meeting incorporating the 31st International Workshop on Surfactant Replacement took place in Naples from June 3–4, 2016. It is fitting that this meeting should be held in Italy where the surfactant poractant alfa is manufactured for the treatment of preterm infants with respiratory distress syndrome worldwide [1]. Naples is Italy’s third largest city after Rome and Milan. It is also famous for being one of the oldest cities in the world with great artistic merits.

The meeting started with the 8th Bengt Robertson Memorial Lecture given by Virgilio P. Carnielli from Ancona, Italy. His lecture was entitled ‘Neonatal Respiratory Diseases in the Newborn Infant: Novel Insights from Stable Isotope Tracer Studies’ [2]. Apart from respiratory distress syndrome, which is due to a primary deficiency of pulmonary surfactant, the pathogenesis of a variety of other neonatal respiratory disorders may involve secondary surfactant dysfunction. Studies by Carnielli and his colleagues using stable isotope tracers have increased our understanding of surfactant metabolism in many of these respiratory disorders of the newborn, including pneumonia, meconium aspiration syndrome and congenital diaphragmatic hernia. Results from these studies may lead to a widening of the clinical indications for surfactant therapy, something that would have greatly pleased Bengt Robertson, in whose name the lecture was given.

The second invited speaker was Robin H. Steinhorn from Washington, D.C., USA, who discussed advances in the pathogenesis and treatment of neonatal pulmonary hypertension [3]. Persistent pulmonary hypertension of the newborn is more common than realised and affects both term and preterm infants. Although there have been numerous recent therapeutic advances in the past decade, there is still no magic bullet. Once the mainstay of treatment to cause pulmonary vasodilatation, oxygen is now known to have both risks and benefits. Exogenous surfactant and inhaled nitric oxide may be useful for less severe pulmonary hypertension, and both reduce the need for extracorporeal membrane oxygenation. Other drugs with potential to benefit infants with pulmonary hypertension include milrinone, sildenafil and hydrocortisone. Steinhorn concluded that continued laboratory and clinical investigation will be needed.
The next two invited speakers from Italy discussed different forms of non-invasive ventilation [12, 13]. Corrado Moretti from Rome spoke about synchronised intermittent positive pressure ventilation, concentrating on technical issues and clinical outcomes, whereas Gianluca Lista from Milan discussed the place of sustained inflation in the delivery room management of preterm infants. Avoiding mechanical ventilation is a critical goal in reducing the incidence of bronchopulmonary dysplasia. To this end a number of means of non-invasive respiratory support have been developed. In general, the newer modes of non-invasive ventilation are more effective than nasal continuous positive airway pressure in reducing extubation failure, and may also have a role as primary support to manage respiratory distress syndrome after surfactant therapy and for treatment of apnoea of prematurity. In the delivery room in order to prevent lung injury and to enhance the success of continuous positive airway pressure, sustained inflation by face mask or nasopharyngeal tube (20–25 cm H2O for 10–15 s) has recently been suggested to establish an early functional residual capacity. Studies to date have produced conflicting results and Lista was cautious about recommending its use in routine clinical practice.

Rangasamy Ramanathan from Los Angeles, Calif., USA, reviewed therapeutic strategies for retinopathy of prematurity (ROP) [14]. He believes that understanding the pathophysiology of ROP is critical in the planning of appropriate therapeutic interventions. In phase I ROP there is vaso-obliteration soon after birth due to a marked decrease in vascular endothelial growth factor (VEGF) and insulin-like growth factor. In phase II ROP, beginning at about 33 weeks’ postmenstrual age, VEGF levels increase especially when there has been retinal hypoxia leading to abnormal vasoproliferation. Ramanathan proposed that oxygen saturation targets should vary according to the phase of ROP, so that a lower saturation could be used during phase I, whereas higher target oxygen saturation may be effective in reducing rates of disabling ROP in phase II. This theory will need to be tested in prospective randomised controlled trials [8]. Other therapeutic agents being studied include insulin-like growth factor-1 and propranolol. For advanced ROP, laser ablation of avascular retina or intravitreal injection of an anti-VEGF antibody, such as bevacizumab, and vitrectomy are used to protect central vision and retinal detachment.

The final talk of the SPIN Meeting was by Won Soon Park from Seoul, who discussed stem cell treatment for neonatal brain disorders [15]. This presentation was a logical continuation of Ferreiro’s talk, who had set the
scene by explaining the vulnerability of the neonatal brain [4]. Stem cell therapy is a promising novel therapy for neonatal brain injury resulting from intraventricular haemorrhage and hypoxia-ischaemia. Park presented preclinical data, covering important issues for clinical translation such as cell type, route of administration, dose and timing of stem cell therapy, and translation of these preclinical results into clinical trials.

The SPIN Update comprised four excellent talks on important topics in neonatology. Pierre Gressens from Paris discussed controversies in preterm brain injury, Petra Huppi from Geneva presented the effects of fetal growth retardation on brain structure and neurodevelopmental outcome, Karel Allegaert from Leuven talked about adverse drug reactions in the neonate and Francesca Raimondi from Naples answered the question: “Is ultrasound useful in the diagnosis of newborn lung disease?”

The SPIN meeting also comprised 18 short oral communications and 24 poster presentations. Some of the review papers from the meeting and the free oral communications are published in this issue of *Neonatology*. We would like to remember again Bengt Robertson who founded this series of workshops in 1986 and was architect of our understanding of neonatal RDS and its treatment with surfactant [16]. He would be delighted to see how workshops on surfactant have evolved into a meeting that now shares progress in neonatology with a much wider audience. The second SPIN meeting is scheduled to be in Dublin in 2017.

**Disclosure Statement**

The scientific program was arranged by the Scientific Committee without interference from the sponsors. All members of the Scientific Committee are or have been consultants to Chiesi Farmaceutici. The content of the meeting and workshop reflects the scientific opinions of the individual presenters and not the sponsor or its partners.

**References**